Reducing Pain and Opioid Use With CBD

Summary

This is a double-blind, placebo-controlled, parallel group study designed to assess the tolerability and efficacy of fsCBD and bsCBD, compared to a placebo control, to reduce opioid use, anxiety, and pain and improve sleep and cognitive function. If eligible for the study, subjects will be randomized to receive one of the conditions for 12 weeks.

Timeline

Start

2022-03-08

Primary completion

2025-07-29

Completion

2025-08-19

Drugs

Indications